Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Status:
Not yet recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of
cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177
dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation
cabozantinib.